New HIV vaccine trial to start in South Africa

JOHANNESBURG -- A new vaccine against HIV, to be tested in a trial to be launched in South Africa on Wednesday, could be "the final nail in the coffin" for the disease if it is successful, scientists say.

The study, called HVTN 702, aims to enroll 5,400 sexually active men and women aged between 18 and 35 at 15 sites across South Africa.

It will be the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people a day are infected with HIV.

"If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," Anthony Fauci, director of the U.S. government's National Institute of Allergy and Infectious Diseases (NIAID), said in a statement released before the trial.

"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa," he said.

The vaccine being tested in HVTN 702 is based on a 2009 trial in Thailand, that was found to be 31.2 percent effective at preventing HIV infection over the 3.5 years of follow-up after the vaccination.

The new vaccine aims to provide greater and more sustained protection and has been adapted to the HIV subtype that predominates in southern Africa.

"HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country,"said Glenda Gray, chief executive officer of the South African Medical Research Council.